LipoMedix
Liposome Delivery for Cancer Therapy
StartupLipoMedix is a Jerusalem-based startup in the Health Tech & Life Sciences sector, established in 2011. Liposome Delivery for Cancer Therapy . The company has raised a total of $56K across 1 funding round, currently at the Pre-Funding stage. LipoMedix was founded by Al Gabizon and Rami Kremien. The company has 1-10 employees. Core technologies: Biologicals.
With $56K in total funding, LipoMedix is a Pre-Funding-stage company operating in Health Tech & Life Sciences. The company follows a B2B business model. Product stage: Clinical Trial. The company holds 1 patent.
- StagePre-Funding
- ProductClinical Trial
- ModelB2B
- Employees1-10
- HQJerusalem
- DistrictJerusalem District
- Last Round$56K
Al GabizonFounder & President
Rami KremienCo-founder
4 articles covered by sources including www.globenewswire.com.
What does LipoMedix do?
LipoMedix Pharmaceuticals is a privately held development-stage company focused on an innovative, safe, and effective cancer therapy based on liposome delivery. The companys lead product, Promitil, has demonstrated antitumor effects in tumor models that rival or outperform the effects of many standard forms of chemotherapy, such as cisplatin, irinotecan, gemcitabine, and doxorubicin, with less toxicity.
How much funding has LipoMedix raised?
LipoMedix has raised $56K in total funding across 1 rounds. The company is currently at the Pre-Funding stage.
Who founded LipoMedix?
LipoMedix was founded in 2011 by Al Gabizon (Founder & President), Rami Kremien (Co-founder).
What sector is LipoMedix in?
LipoMedix operates in Health Tech & Life Sciences, Pharma & Medical Biotechnology, Drug Delivery, with core technologies in Biologicals. Target customers: Healthcare & Life Sciences, Life Sciences, Pharmaceuticals.
Where is LipoMedix located?
LipoMedix is based in Giv'at Ram, Jerusalem, Israel, Jerusalem District.